WORCESTER, Mass., Aug. 27, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) ( www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today made available the following letter to stockholders relating to the special meeting to be held on September 17, 2010: August 27, 2010 Dear Stockholder: We recently mailed you proxy materials for the special meeting of stockholders to be held on Friday, September 17, 2010 to consider the following items of business:
- To approve an amendment to our Restated Certificate of Incorporation (i) to effect a reverse stock split of our common stock, at an exchange ratio of not less than 1-for-2 and not more than 1-for-10 at any time prior to September 16, 2011 (the implementation of the reverse stock split, ratio and timing of which will be subject to the discretion of the Board of Directors), and (ii) following the reverse stock split, if implemented, to reduce the number of authorized shares of common stock from 750,000,000 to 500,000,000 unless the Board of Directors utilizes a ratio of not more than 1-for-2, in which case, the number of authorized shares of common stock will be maintained at 750,000,000.
- To approve the adjournment of the Generex special meeting, if necessary, to solicit additional proxies for the foregoing proposal; and
- To conduct any other business as may properly come before the Generex special meeting or any adjournment or postponement thereof.
- Page 1 – What are the items of business for the meeting?
- Page 2 – What if I return my proxy card but do not provide voting instructions?
- Page 4 – What am I voting on?
Very truly yours,/s/ Rose C. Perri Rose C. Perri Secretary About Generex Biotechnology Corporation Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). Generex's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using Generex's proprietary RapidMist™ device. Generex's flagship product, buccal insulin (Generex Oral-lyn™), which has been approved in Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com . Information contained in, or accessible through, the websites of Generex or Antigen Express is not incorporated herein and is not a part of the proxy soliciting material. The Generex Biotechnology Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3831
CONTACT: American Capital Ventures, Inc. Investor Relations Contact: Howard Gostfrand 1-877-918-0774 Beckerman Media Contact: Christina Brozek 201-452-4849